Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

Reck, Martin; Rabe, Klaus F.

doi:10.1056/nejmra1703413

Cited by 569 publications

(454 citation statements)

References 68 publications

Supporting

Mentioning

446

Contrasting

Unclassified

Order By: Relevance

“…Lung cancer remains one of the most frequent and most deadly tumor entities, with 1.6 million tumor-related deaths annually worldwide [1]. Lung cancer comprises small cell lung cancer (SCLC), which accounts for approximately 15% of all lung cancers and non-small cell lung cancer (NSCLC), which accounts for approximately 85% [2].…”

Section: Introductionmentioning

confidence: 99%

lncRNA AFAP1-AS1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via Up-Regulating IRF7 and the RIG-I-Like Receptor Signaling Pathway

Tang

Zhang

Jia

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Accumulating evidence has highlighted the importance of long non-coding RNAs (lncRNAs) as competing endogenous RNAs (ceRNAs) in tumor biology. Among others, actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) has been associated with non-small cell lung cancer (NSCLC). However, it remains unclear how AFAP1-AS1 participates in the development and progression of NSCLC. Methods: The peripheral blood samples were collected from patients with NSCLC. White blood cell subsets were classified and levels of interleukin (IL)-10, IL-12 and IFN-γ in serum were measured. We then identified its target gene of AFAP1-AS1 via bioinformatics methods. NSCLC cell line with the highest expression of AFAP1-AS1, i.e. H1975 was selected for in vitro experiments. A series of inhibitor, vector and siRNA were employed to validate the regulatory mechanisms of AFAP1-AS1 in the development and progression of NSCLC. Cell proliferation was detected by MTT assay and EdU staining. Cell migration and invasion, and cell cycle and apoptosis were measured by transwell assay and flow cytometry, respectively. Results: A high expression of AFAP1-AS1 was identified in NSCLC, alongside with a reduced level of IL-12 and increased levels of IL-10 and interferon (IFN)-γ. Aberrant expressions of AFAP1-AS1 were associated with pathological grade, TNM staging and metastatic potential of NSCLC. AFAP1-AS1 could activate interferon regulatory factor (IRF)7, the retinoid-inducible protein (RIG)-I-like receptor signaling pathway and Bcl-2 in vitro. Over-expression of AFAP1-AS1 promoted NSCLC cell proliferation, invasion and migration while inhibiting cell apoptosis. Conclusion: lncRNA AFAP1-AS1 promotes migration and invasion of non-small cell lung cancer via up-regulating IRF7 and the RIG-I-like receptor signaling pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

lncRNA AFAP1-AS1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via Up-Regulating IRF7 and the RIG-I-Like Receptor Signaling Pathway

Tang

Zhang

Jia

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…On the basis of the molecular knowledge of lung cancer, specifically targeted treatments besides traditional surgery or radiotherapy, promote positive therapeutic outcomes [7]. For example, various small molecule drugs have been designed to tackle all possible situations, such as gefitinib and erlotinib [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Peptide 17, an inhibitor of YAP/TEAD4 pathway, mitigates lung cancer malignancy

Zhang¹,

Pan²,

Liao³

et al. 2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Over the last 10 years, significant progress has been made and several new drugs have been approved for treatment of non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors have not only revolutionized secondline treatment but are now also approved in the first-line setting [1]. However, not every patient benefits from immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…The detection of molecular alterations including EGFR or BRAF mutations and EML4-ALK or ROS1 rearrangements and subsequent target-specific treatment also improved survival for these patients. However, the benefit of molecular targeted therapies has largely been restricted to a small group of patients (10-20%) [1].…”

Section: Introductionmentioning

confidence: 99%

Anti-Angiogenics: Their Value in Lung Cancer Therapy

Janning

Loges

2018

Oncol Res Treat

View full text Add to dashboard Cite

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved for second-line treatment in combination with docetaxel. This review provides a summary of pivotal trials with anti-angiogenic drugs in NSCLC in different settings. We give an overview of how to position anti-angiogenic therapy in the current treatment algorithms and highlight future directions. The identification of predictive biomarkers for patient selection could improve the success of anti-angiogenic drugs and represents an important area of research. In addition, novel therapeutic targets including endothelial metabolomic intermediates and cellular components of the tumor microenvironment could lead to the identification of innovative new targets besides the VEGF axis.

show abstract

Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

Cited by 569 publications

References 68 publications

lncRNA AFAP1-AS1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via Up-Regulating IRF7 and the RIG-I-Like Receptor Signaling Pathway

lncRNA AFAP1-AS1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via Up-Regulating IRF7 and the RIG-I-Like Receptor Signaling Pathway

Peptide 17, an inhibitor of YAP/TEAD4 pathway, mitigates lung cancer malignancy

Anti-Angiogenics: Their Value in Lung Cancer Therapy

Contact Info

Product

Resources

About